Comparative Pharmacology
Head-to-head clinical analysis: AMANTADINE versus APOGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMANTADINE versus APOGEN.
AMANTADINE vs APOGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amantadine is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of viral uncoating, thereby blocking influenza A M2 ion channel. In Parkinson's disease, it is thought to increase dopamine release and inhibit its reuptake, and may also have anticholinergic and NMDA receptor antagonist effects.
Apocynin is a prodrug that is activated by peroxidases to form dimers that inhibit NADPH oxidase (NOX) enzyme complexes, reducing superoxide production. It also exhibits antioxidant and anti-inflammatory properties.
100 mg orally twice daily for Parkinson's disease; 100 mg orally twice daily for influenza A prophylaxis/treatment (up to 200 mg/day).
10 mg orally once daily, with or without food.
None Documented
None Documented
Clinical Note
moderateAmantadine + Haloperidol
"The therapeutic efficacy of Haloperidol can be decreased when used in combination with Amantadine."
Clinical Note
moderateAmantadine + Mifepristone
"Amantadine may increase the QTc-prolonging activities of Mifepristone."
Clinical Note
moderateAmantadine + Promazine
"The therapeutic efficacy of Promazine can be decreased when used in combination with Amantadine."
Clinical Note
moderateAmantadine + Chlorpromazine
Terminal elimination half-life: 10-14 hours in young adults, up to 24 hours in elderly; prolonged to >24 hours in renal impairment
Terminal half-life 3.5 hours; dose adjustment required in renal impairment (CrCl <30 mL/min).
Renal: 90% as unchanged drug via glomerular filtration and tubular secretion; fecal: <10%
Renal: 90% unchanged; fecal: 10% as metabolites.
Category C
Category C
Antiviral / Antiparkinsonian
Antiviral
"The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Amantadine."